Literature DB >> 17217333

Cytokine therapy for Crohn's disease: advances in translational research.

Theresa T Pizarro1, Fabio Cominelli.   

Abstract

Crohn's disease (CD) and ulcerative colitis (UC), the two idiopathic inflammatory bowel diseases (IBDs), affect almost two million individuals in North America and several million worldwide. Cytokines are important in the pathogenesis of CD, and their manipulation has successfully reduced disease severity and maintained remission. Following the discovery of novel cytokines and the role they may play in gut mucosal immunity, as well as the emergence of new concepts and changing paradigms in CD pathogenesis, the roles of several cytokines have been elucidated and tested in both preclinical animal models and clinical trials of patients with IBD. Complementary to this, proof of concept for new cytokine targets is rapidly developing, with the possibility of future cytokine-based therapies that may offer greater specificity and decreased toxicity for the treatment of CD. This review discusses novel concepts in CD pathogenesis and the roles of cytokines in the initiation and perpetuation of disease. In addition, we review applications of cytokine-based therapies in human clinical trials and preclinical animal studies. Finally, we discuss novel cytokine targets not yet investigated in vivo and describe their potential contribution to CD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17217333     DOI: 10.1146/annurev.med.58.121205.100607

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  37 in total

1.  Paradoxical effects of constitutive human IL-32{gamma} in transgenic mice during experimental colitis.

Authors:  Jida Choi; Suyoung Bae; Jaewoo Hong; Soyoon Ryoo; Hyunjhung Jhun; Kwangwon Hong; Doyoung Yoon; Siyoung Lee; Erk Her; Wonhyuk Choi; Jeonghwan Kim; Tania Azam; Charles A Dinarello; Soohyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

Review 2.  Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy.

Authors:  M-I Torres; A Rios
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

3.  Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.

Authors:  Ida Ricciardelli; Keith J Lindley; Marco Londei; Sonia Quaratino
Journal:  Immunology       Date:  2008-04-16       Impact factor: 7.397

4.  Clcn5 knockout mice exhibit novel immunomodulatory effects and are more susceptible to dextran sulfate sodium-induced colitis.

Authors:  Philip Alex; Mei Ye; Nicholas C Zachos; Jennifer Sipes; Thuan Nguyen; Maxim Suhodrev; Liberty Gonzales; Zubin Arora; Ting Zhang; Michael Centola; Sandra E Guggino; Xuhang Li
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

5.  Dual TNF-α/IL-12p40 Interference as a Strategy to Protect Against Colitis Based on miR-16 Precursors With Macrophage Targeting Vectors.

Authors:  Zhen Huang; Junting Ma; Mengjie Chen; Haoyang Jiang; Yong Fu; Jingjing Gan; Lei Dong; Junfeng Zhang; Jiangning Chen
Journal:  Mol Ther       Date:  2015-06-15       Impact factor: 11.454

6.  The signaling axis of microRNA-31/interleukin-25 regulates Th1/Th17-mediated inflammation response in colitis.

Authors:  T Shi; Y Xie; Y Fu; Q Zhou; Z Ma; J Ma; Z Huang; J Zhang; J Chen
Journal:  Mucosal Immunol       Date:  2016-11-30       Impact factor: 7.313

7.  Targeting IL-12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis.

Authors:  Qingdong Guan; Yanbing Ma; China-Li Hillman; Gefei Qing; Allan G Ma; Carolyn R Weiss; Gang Zhou; Aiping Bai; Richard J Warrington; Charles N Bernstein; Zhikang Peng
Journal:  Mol Med       Date:  2011-03-11       Impact factor: 6.354

8.  Reversing Ongoing Chronic Intestinal Inflammation and Fibrosis by Sustained Block of IL-12 and IL-23 Using a Vaccine in Mice.

Authors:  Qingdong Guan; Carolyn R Weiss; Shuhe Wang; Gefei Qing; Xi Yang; Richard J Warrington; Charles N Bernstein; Zhikang Peng
Journal:  Inflamm Bowel Dis       Date:  2018-08-16       Impact factor: 5.325

Review 9.  IL-32θ: a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity.

Authors:  Muhammad Babar Khawar; Maryam Mukhtar; Muddasir Hassan Abbasi; Nadeem Sheikh
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

10.  A model for chronic mucosal inflammation in IBD and periodontitis.

Authors:  Helieh S Oz; Theresa Chen; Jeffrey L Ebersole
Journal:  Dig Dis Sci       Date:  2009-11-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.